title: Monoclonal antibodies: versatile platforms for cancer immunotherapy.
abstract: Antibodies are important therapeutic agents for cancer. Recently, it has become clear that antibodies possess several clinically relevant mechanisms of action. Many clinically useful antibodies can manipulate tumour-related signalling. In addition, antibodies exhibit various immunomodulatory properties and, by directly activating or inhibiting molecules of the immune system, antibodies can promote the induction of antitumour immune responses. These immunomodulatory properties can form the basis for new cancer treatment strategies.
authors.affiliation: Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA. weinerl@georgetown.edu
authors.forename: Louis M
authors.initials: LM
authors.lastname: Weiner
authors.forename: Rishi
authors.initials: R
authors.lastname: Surana
authors.forename: Shangzi
authors.initials: S
authors.lastname: Wang
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000627:therapeutic use*; D000920:Antibody-Dependent Cell Cytotoxicity; D015703:Antigens, CD / Q000276:immunology; D019013:CD40 Antigens / Q000037:antagonists & inhibitors; D060908:CTLA-4 Antigen; D019496:Cancer Vaccines / Q000627:therapeutic use; D003165:Complement System Proteins / Q000276:immunology; D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D019013:CD40 Antigens; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D019496:Cancer Vaccines; D003165:Complement System Proteins